Clinical Trial Update: A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study evaluating pharmacokinetics and safety of BR2022 and BR2022-1 in patients with deleterious BRCA-mutated advanced ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• BR2022
• BR2022-1

Snippet

Sponsor: Boryung Pharmaceutical Co., Ltd | Conditions: Ovarian Cancer | Phase 1 | Status: RECRUITING